Advisory Research Inc Geron Corp Transaction History

Advisory Research Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.11 - $3.28 $1.44 Million - $2.25 Million	-684,653 Reduced 74.31%	236,682 $501,000
Q2 2023 Aug 14, 2023	BUY	$1.97 - $3.69 $840,321 - $1.57 Million	426,559 Added 86.21%	921,335 $2.96 Million
Q1 2023 May 12, 2023	BUY	$2.14 - $3.4 $637,189 - $1.01 Million	297,752 Added 151.12%	494,776 $1.07 Million
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $329,030 - $579,250	197,024 New	197,024 $461,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.